Uncategorised - European Medical Journal

Doctor examining birthmarks and moles patient. examination of birthmarks and moles.

Skin Cancer Screening Tool Gains Ground in Transplant Care

A new skin cancer risk stratification tool for solid organ transplant recipients shows strong international validation but inconsistent clinical adoption.

Doctor reviewing latent tuberculosis infection risk factors with a patient who has type 2 diabetes

Hospital Study Links Diabetes to Latent Tuberculosis Infection

Latent tuberculosis infection was common in type 2 diabetes, with poor glycemic control linked to higher risk.

Latest Census Exposes Consultant Psychiatrist Shortage in England

One in seven consultant psychiatrist posts are vacant across England, leading to barriers to vital care for patients with mental illness.

night shift

Night Shift Work Impacts Type 2 Diabetes Management

Night shift work in type 2 diabetes is linked to higher glucose variability, increased snacking, and prolonged wakefulness, underscoring the need for tailored care strategies.

Hema Now: The Next Era of Paediatric Haemophilia Management

In this episode of Hema Now, Marilyn Manco-Johnson explores the evolution and future of paediatric haemophilia care…

Mental Health Misinformation Widespread on Social Media

Researchers found that the prevalence of mental health misinformation ranged from 0% to 56.9%, highlighting substantial variability in content accuracy.

Peter-Chedraui

ISGE 2026 Interview: Peter A. Chedraui

Although I did not complete a formal fellowship, I undertook several courses in maternal–fetal medicine at New York University Langone…

MRI Before Prostate Surgery Predicts Cancer Outcomes

Pre-treatment prostate MRI predicts recurrence and survival outcomes after radical prostatectomy, offering added prognostic value beyond standard clinical factors.

Brain Age Index from Sleep EEG Predicts Dementia Risk

Meta-analysis shows brain age index from sleep EEG predicts dementia risk, supporting its use as an early digital biomarker.

Novo Nordisk launches higher-dose semaglutide

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, following FDA approval on 19 March.